The influence of Infliximab on the development of Experimental Pancreatitis

Article Sidebar

PDF HTML
Submitted: July 28, 2017
Published: Aug 25, 2017
DOI: 10.29328/journal.hcg.1001003
Keywords:
Rat, Pancreatic duct, Motor function, Pancreatitis, Infliximab

Main Article Content

Lychkova AE
Head of Department of Moscow’s Clinical Scientific Center, Moscow Health Department, Russia
Golubev Yu Yu
Associate Professor, Department of Propaedeutics Russian National Research Medical University, N.I. Pirogov, Russia
Puzikov AM
Collaborator, Department of Moscow’s Clinical Scientific Center, Moscow Health Department, Russia

Abstract

Aim: To identify the possibility of correction of motor function of the gastro-intestinal tract in experimental pancreatitis with the administration of infliximab.


Material and methods: Pancreatitis was modeled by the administration of picrylsulfonic acid retrogradely into the pancreatic duct of rat (n=5) and 4 animals were control. Electromyogram (EMG) of the pancreatic duct was monitored immediately after the administration of picrylsulfonic acid and on the 15th day of pancreatitis simulation before and after the administration of infliximab. The morphological investigation of pancreas was conducted on the 15th day of development of pancreatitis and on the 15th day of treatment of pancreatitis with infliximab.


Results: Infliximab restores the motor function of pancreatic duct and structure of pancreas during acute pancreatitis.


Conclusion: Protective action of infliximab during acute pancreatitis was shown.

Article Details

AE, L., Yu Yu, G., & AM, P. (2017). The influence of Infliximab on the development of Experimental Pancreatitis. Annals of Clinical Gastroenterology and Hepatology, 1(1), 007–011. https://doi.org/10.29328/journal.hcg.1001003
Research Articles

Copyright (c) 2017 Lychkova AE, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Schäfer C, Tietz AB, Göke B. Pathophysiology of acute experimental pancreatitis: lessons from genetically engineered animal models and new molecular approaches. Digestion.2005; 71: 162-172. Ref.: https://goo.gl/JWEVUq

Lee JU, Shin W, Son JY, Yoo KY, Heo YS. Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases. Int J Mol Sci. 2017; 18: 228. Ref.: https://goo.gl/x4GARQ

Ou X, Cheng Z, Liu T, Tang Z, Huang W, et al. Circulating Histone Levels Reflect Disease Severity in Animal Models of Acute Pancreatitis. Pancreas. 2015; 44: 1089-1095. Ref.: https://goo.gl/sDEabp

Fantini L, Tomassetti P, Pezzilli R. Management of acute pancreatitis: current knowledge and future perspectives. World J Emerg Surg. 2006; 23: 1-16. Ref.: https://goo.gl/BrDMia

Ozhan G, Yanar HT, Ertekin C, Alpertunga B. Polymorphisms in tumor necrosis factor alpha (TNFalpha) gene in patients with acute pancreatitis. Mediators Inflamm. 2010; 2010: 482950. Ref.: https://goo.gl/h2ekXm

Maev IV, Kucheryavy Yu A. Drug therapy for chronic pancreatitis. News of medicine and pharmacy. 2007; 218: 14-16.